Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | PARG | Q86W56 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | APAF1 | O14727 | 1/20 | 0.42 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28965644 | 0.82 | ALDH1A1 (0.54) | LMNAL3MBTL1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL31710152 | 0.82 | LMNA (0.48) | LMNAL3MBTL1ALDH1A1PARGSMN1; SMN2 | |
| SCHEMBL15999448 | 0.77 | HSD17B10 (0.60) | LMNAL3MBTL1ALDH1A1PARGGAA | |
| SCHEMBL5418830 | 0.76 | CCNB2 (0.44) | LMNAL3MBTL1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL7479161 | 0.74 | MCL1 (0.47) | LMNAL3MBTL1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL474471 | 0.74 | MEN1 (0.55) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL5431370 | 0.73 | ALDH1A1 (0.51) | LMNAALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL28965728 | 0.73 | ALDH1A1 (0.60) | LMNAL3MBTL1ALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27034561 | 0.72 | ALDH1A1 (0.42) | LMNAL3MBTL1ALDH1A1SMN1; SMN2MEN1 | |
| SCHEMBL17845670 | 0.71 | PARG (1.00) | PARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191447-A1 | Novel heterocyclic compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1719761-A1 | NOVEL HETEROCYCLIC COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-11-08 | — | — | EP | disclosed |
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | BENDER DAVID MICHAEL (US) | 2003-12-04 | — | — | US | disclosed |
| EP-1309577-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2003-05-14 | — | — | EP | disclosed |
| WO-2002014294-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191447-A1 | Novel heterocyclic compound | OPRD1, GRIN3A, GRM3 | LMNA 3597/4885L3MBTL1 4071/4885ALDH1A1 1154/4885 |
| US-20030225127-A1 | Heterocyclic sulfonamide derivatives | GRIN2A, GRIN2B, GRIN1 | LMNA 4816/4885L3MBTL1 4768/4885ALDH1A1 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.